**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 26850**

**Manuscript Type: Original Article**

***Retrospective Study***

**Bleeding risk with clopidogrel and percutaneous endoscopic gastrostomy**

Sohail U *et al.* Percutaneous endoscopic gastrostomy on clopidogrel

**Umair Sohail, Chela Harleen, Amin O Mahdi, Murtaza Arif, Douglas L Nguyen, Matthew L Bechtold**

**Umair Sohail, Chela Harleen, Amin O Mahdi, Murtaza Arif, Matthew L Bechtold,** Department of Medicine, University of Missouri, Columbia, MO 65212, United States

**Douglas L Nguyen,** Department of Medicine, University of California, Irvine, CA 92697, United States

**Author contributions:** Sohail U, Arif M and Bechtold ML contributed to conception and design; Sohail U, Harleen C and Mahdi AO contributed to acquisition of data and drafting of manuscript; Sohail U, Arif M, Nguyen DL and Bechtold ML contributed to analysis and interpretation of data; Arif M, Nguyen DL and Bechtold ML contributed to critical revision of manuscript; Nguyen DL and Bechtold ML contributed to statistical expertise; Bechtold ML contributed to overall supervision of project.

**Institutional review board statement:** IRB reviewed and approved this project as a record review.

**Informed consent statement:** Given the nature of the retrospective record review, no informed consent was mandated per IRB.

**Conflict-of-interest statement:** No conflicts of interest noted.

**Data sharing statement:** Dataset is available from the corresponding author, Matthew Bechtold at [bechtoldm@health.missouri.edu](mailto:bechtoldm@health.missouri.edu). Given that is a retrospective study, informed consent was not obtained for data sharing but data was anonymized and project approved by the IRB.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Matthew L Bechtold, MD, FACP, FASGE, FACG, AGAF,** Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri, CE405, DC043.00, Five Hospital Drive, Columbia, MO 65212, United States. [bechtoldm@health.missouri.edu](mailto:bechtoldm@health.missouri.edu)  
**Telephone:** +1-573-8821013

**Fax:** +1-573-8844595

**Received:** April 28, 2016

**Peer-review started:** April 29, 2016

**First decision:** May 17, 2016

**Revised:** June 1, 2016

**Accepted:** June 27, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To compare bleeding within 48 h in patients undergoing percutaneous endoscopic gastrostomy (PEG) with or without clopidogrel.

**METHODS:** After institutional review board (IRB) approval, a retrospective study involving a single center was conducted on adult patients having PEG (1/08-1/14). Patients were divided into two groups: Clopidogrel group consisting of those patients taking clopidogrel within 5 d of PEG and the non-clopidogrel group including those patients not taking clopidogrel within 5 d of the PEG.

**RESULTS:** Three hundred and nineteen PEG patients were found. One hundred and sixty-eight males and 151 females with mean body mass index 28.47 ± 9.75 kg/m2 and mean age 65.03 ± 16.11 years were identified. Thirty-three patients were on clopidogrel prior to PEG with 286 patients not on clopidogrel. No patients in either group developed hematochezia, melena, or hematemesis within 48 h of PEG. No statistical differences were observed between the two groups with 48 h for hemoglobin decrease of > 2 g/dL (2 *vs* 5 patients; *P* = 0.16), blood transfusions (2 *vs* 7 patients; *P* = 0.24), and repeat endoscopy for possible gastrointestinal bleeding (no patients in either group).

**CONCLUSION:** Based on the results, no significant post-procedure bleeding was observed in patients undergoing PEG with recent use of clopidogrel.

**Key words:** Percutaneous endoscopic gastrostomy; Clopidogrel; Bleeding; Complications; Antiplatelets

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Percutaneous endoscopic gastrostomy (PEG) is a common but invasive procedure. In the past, many medications were held prior to the procedure to reduce the risk of potential bleeding complication, such as clopidogrel. Much debate has been performed regarding the need for cessation of clopidogrel prior to PEG placement with little evidence found in the literature. This manuscript showed that clopidogrel use in patients undergoing PEG placement had no increased early post-procedure bleeding risk.

Sohail U, Harleen C, Mahdi AO, Arif M, Nguyen DL, Bechtold ML. Bleeding risk with clopidogrel and percutaneous endoscopic gastrostomy. *World J Gastrointest Endosc* 2016; In press

**INTRODUCTION**

Percutaneous endoscopic gastrostomy (PEG) is most commonly performed to provide nutritional support to patients who fail to swallow for a long time requiring tube feeding support[1]. This procedure was first reported by Gauderer *et al*[2] in 1980. Since then PEG has become an important technique for inserting feeding tubes in patients with swallowing difficulties who require long term nutritional support without undergoing laparotomy[2,3]. The placement of PEG tube is classified among high-risk endoscopic procedure because of the risk of associated clinically significant bleeding. The enteric tube can be placed surgically, under radiological guidance or by endoscopic technique. When compared, the endoscopic technique has the least overall risk[4]. Due to having the least overall risk, it is considered to be the technique of choice. However, endoscopic procedures may be low or high risk procedures. High risk endoscopic procedures are ones which are associated with the risk of bleeding being > 1%. PEG is considered a high risk procedure and carries a 2.5% risk of complications[3]. PEG tube is usually required in patients who are elderly and have multiple comorbidities. These patients are usually on antithrombotic agents or anticoagulants and hence are at increased risk of procedure-related bleeding. At the same time, holding the antiplatelet or anticoagulant agents could have potential thromboembolic complications from the underlying pro-thrombotic state. These medications for various cerebrovascular, cardiovascular, and hematological disorders has drastically increased[3].These agents significantly increase gastrointestinal (GI) bleeding risk. However, a recent study revealed that the incidence of bleeding after a PEG placement appears to be similar at 2.8%[5].Based on literature review, PEG post-procedure bleeding risk is estimated to be 2%-2.5%[6,7]. According to current guidelines, clopidogrel discontinuation for 7-10 d prior to PEG in patients with underlying low thromboembolic risks is recommended[6-8]***.***

In case of high underlying thromboembolic risk, it is recommended to consider postponing the procedure until it is safe to hold the thienopyridines (clopidogrel, *etc*.). They should be held for 7-10 d when the underlying risk is low. In patients taking dual antiplatelet therapy, it is safe to continue aspirin while holding the clopidogrel. In cases where patients are on monotherapy with thienopyridines, these patients can be started on aspirin during peri-procedure period.

The patterns of clinical practice for the management of these medications differ from these recommendations. Differences also exist in the patterns of practice among gastroenterologists themselves in the use of these agents. An international survey that was conducted in 2008 revealed that differences exist between Western and Eastern countries with regards to management of these agents[9].

To further evaluate the use of clopidogrel in PEG placement, we performed a retrospective study examining the potential post-procedure risks of bleeding.

**MATERIALS AND METHODS**

A retrospective study was conducted at a single tertiary-care center on all adult patients having PEG placement (January 2008-January 2014). Institutional review board approval was obtained. PEG was performed by using the standard push or pull technique[2]. The procedure was performed by the attending gastroenterologist and the gastroenterology fellow at our tertiary-care center. All patients were nothing per mouth from midnight to the procedure and received a prophylactic antibiotic 30 min prior to the procedure (if not already receiving antibiotic treatment at the time of PEG insertion for any other reason).

The data pertaining to the several parameters was collected. These included patient demographics, indication for PEG placement, comorbid illnesses, and laboratory data, including hematology profile (hemoglobin, platelets, and coagulation values). The use of each antiplatelet drug was noted and data regarding the timing of the last dose prior to PEG placement and the first dose following PEG was also recorded. Patients were divided into two groups: Clopidogrel group consisting of those patients taking clopidogrel within 5 d prior to the PEG and the non-clopidogrel group including those patients not taking clopidogrel within 5 d of the PEG.

Procedure-related complications, repeat endoscopy, and blood transfusions < 48 h of PEG was collected. The complications were classified as early (< 48 h of PEG placement) *vs* late (> 48 h). GI bleeding was defined as hemoglobin (hgb) drop > 2 g/dL from baseline, observation of GI bleeding (hematochezia, melena, hematemesis), required blood transfusion, and endoscopic hemostasis. The severity of bleeding was defined as mild (clinical evidence of bleeding, no transfusion required), moderate (transfusion required, less than 4 units, but no surgery required) and severe (transfusion of more than 5 units, radiological or surgical intervention).

Statistical analysis was conducted using the following: Descriptive statistics (demographics), two-tailed unpaired t-test (continuous data), and Fisher’s exact test (categorical data). Statistical significance was significant at *P* < 0.05. Statistics were reviewed by two biostatisticians (MLB and DLN).

**RESULTS**

Three hundred and nineteen patients with PEG placement were identified, consisting of 168 males, 151 females, mean age 65.03 ± 16.11 years, and mean BMI 28.47 ± 9.75 kg/m2 (Table 1). Thirty-three patients were using clopidogrel (mean age 71.21 ± 11.43 years). Thirty patients out of these 33 patients received a dose of clopidogrel within 5 d prior to the actual day of the procedure, whereas three patients out of 33 received a dose of Plavix within 7 d prior to the procedure. Two hundred and eighty-six patients were not taking clopidogrel (mean age 64.37 ± 16.44 years). Within 48 h of PEG, no patients in either group developed hematochezia, hematemesis, or melena (Table 2). Within 48 h of PEG, decrease in hgb of > 2 g/dL was identified in 2 patients (clopidogrel group) *vs* 5 patients (non-clopidogrel group) (*P* = 0.16). Blood transfusion within 48 h was necessary in 2 patients (clopidogrel group) *vs* 7 patients (non-clopidogrel group) (*P* = 0.24). No patients underwent repeat endoscopy for GI bleeding.

**DISCUSSION**

PEG over the years has emerged as a popular method to provide long-term enteral nutrition to patients. A PEG is required in those with inadequate intake of nutrition but have a normally functioning GI tract[1].

Some of the common indications for placement of a PEG include: Neurological disorders that impair the normal physiology of swallowing, malignancies involving the oropharynx or the esophagus and facial trauma[10-12]. There are several options available when considering placement of a gastrostomy tube. However, the endoscopic technique is preferred due lower incidence of complications and is more cost effective than open surgical gastrostomy[13]. Even though the incidence is less, there are still several complications reported that are secondary to PEG placement[14-17]. In a meta-analysis performed by Wollman *et al*[18], the procedure-related mortality was noted as 0.5% and the 30-d all-cause mortality was 15%. Bleeding is one of the complicating factors contributing to mortality.

Our study focused on the risk of post-PEG placement early bleeding in patients that were already on clopidogrel as compared to those not taking clopidogrel. The study did not reveal any significant increase in the risk of early post-procedure bleeding (occurring within 48 h after the procedure) in patients who were taking clopidogrel. When the data was analyzed according to age (above and below the age of 60) and body mass index (BMI) (more than or less than BMI of 30), there was also no significant differences in the bleeding risks or need for blood transfusions. With this data, the use of clopidogrel should not be considered a contraindication to PEG placement. However, other parameters must be considered prior to PEG in this patient population.

First, prior to performing any endoscopic procedure, the risks and benefits should be thoroughly reviewed, including risk of bleeding[6,7].Second, careful consideration to the clinical impact of withholding an antithrombotic agent must be performed. Hence, each case should be individually evaluated and the decision made after evaluating the pros and cons of proceeding with procedure and holding any antithrombotic agents.

As with any study, strengths and limitations were observed. The strengths include a large amount of patients undergoing PEG placement at a single tertiary-care center over 6 years. However, limitations are observed as well and should be considered when interpreting the results. First, this is retrospective study and not a randomized controlled trial. Certain biases may be involved in accordance to a retrospective study but efforts were done to try to minimize those biases. Second, given the small sample size of patients undergoing PEG while on clopidogrel (*n* = 33), a type II statistical error may be present which indicates the study lacked the power to detect a significant difference between the two groups. However, given that PEG placement has traditionally been withheld on patient who have been on recent clopidogrel, a limited number of patients underwent PEG with clopidogrel over the 6-year period and all of those patients were included in the study. Based on this possibility, results should be interpreted with caution and further larger studies are required to evaluate the overall effect of clopidogrel and PEG placement.

In conclusion, bleeding is a potential complication of PEG placement. Our retrospective study demonstrated no statistically significant increase in bleeding risk or requirement of blood transfusions in patients who were on clopidogrel for PEG placement. Therefore, clopidogrel did not increase bleeding risk despite cessation for a shorter time period as recommended by current guidelines.

**COMMENTS**

***Background***

Percutaneous endoscopic gastrostomy is a common procedure for patients who require enteral supplemental nutrition. In the past, any medications that could lead to increased bleeding risk were held prior to the percutaneous endoscopic gastrostomy (PEG) placement. However, recently, this practice has been challenged, especially with clopidogrel with little evidence in the literature.

***Research frontiers***

Little evidence is in the literature regarding the use of clopidogrel during PEG placement. This retrospective study evaluates the use of concomitant clopidogrel and PEG placement in a tertiary-care hospital in regards to post-procedure bleeding. Very few publications are available in the literature to evaluate this subject. Two publications that are related are below. Lucendo AJ, Sánchez-Casanueva T, Redondo O, Tenías JM, Arias Á. [Risk of bleeding in patients undergoing percutaneous endoscopic gastrotrostomy (PEG) tube insertion under antiplatelet therapy: a systematic review with a meta-analysis.](http://www.ncbi.nlm.nih.gov/pubmed/25733036) *Rev Esp Enferm Dig* 2015; 107: 128-136; Richter JA, Patrie JT, Richter RP, Henry ZH, Pop GH, Regan KA, Peura DA, Sawyer RG, Northup PG, Wang AY. Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel. *Gastrointest Endosc* 2011; 74: 22-34.e1.

***Innovations and breakthroughs***

This is a rare study evaluating the use of clopidogrel with PEG placement. Very few studies have evaluated this subject. This study shows that clopidogrel may not require cessation prior to PEG placement which is a change in current and past practice.

***Applications***

For PEG placement, clopidogrel does not require cessation prior to procedure. This will allow patients to continue their much needed clopidogrel for PEG placement.

***Terminology***

PEG placement is a common procedure performed on patients who require supplemental enteral nutrition. Clopidogrel is also a common medication for antiplatelet properties.

***Peer-review***

The manuscript is provided useful information that clopidogrel discontinuation before PEG is not necessary in case of urgent need for such procedure.

**REFERENCES**

1 **Kirby DF**, Delegge MH, Fleming CR. American Gastroenterological Association technical review on tube feeding for enteral nutrition. *Gastroenterology* 1995; **108**: 1282-1301 [PMID: 7698596 DOI: 10.1016/0016-5085(95)90231-7]

2 **Gauderer MW**, Ponsky JL, Izant RJ. Gastrostomy without laparotomy: a percutaneous endoscopic technique. *J Pediatr Surg* 1980; **15**: 872-875 [PMID: 6780678 DOI: 10.1016/S0022-3468(80)80296-X]

3 **Schapiro GD**, Edmundowicz SA. Complications of percutaneous endoscopic gastrostomy. *Gastrointest Endosc Clin N Am* 1996; **6**: 409-422 [PMID: 8673334]

4 **Lozoya-González D**, Pelaez-Luna M, Farca-Belsaguy A, Salceda-Otero JC, Vazquéz-Ballesteros E. Percutaneous endoscopic gastrostomy complication rates and compliance with the American Society for Gastrointestinal Endoscopy guidelines for the management of antithrombotic therapy. *JPEN J Parenter Enteral Nutr* 2012; **36**: 226-230 [PMID: 21868718 DOI: 10.1177/0148607111413897]

5 **Richter JA**, Patrie JT, Richter RP, Henry ZH, Pop GH, Regan KA, Peura DA, Sawyer RG, Northup PG, Wang AY. Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel. *Gastrointest Endosc* 2011; **74**: 22-34.e1 [PMID: 21704806 DOI: 10.1016/j.gie.2011.03.1258]

6 **Anderson MA**, Ben-Menachem T, Gan SI, Appalaneni V, Banerjee S, Cash BD, Fisher L, Harrison ME, Fanelli RD, Fukami N, Ikenberry SO, Jain R, Khan K, Krinsky ML, Lichtenstein DR, Maple JT, Shen B, Strohmeyer L, Baron T, Dominitz JA. Management of antithrombotic agents for endoscopic procedures. *Gastrointest Endosc* 2009; **70**: 1060-1070 [PMID: 19889407 DOI: 10.1016/j.gie.2009.09.040]

7 **Acosta RD**, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS, Eloubeidi MA, Evans JA, Faulx AL, Fisher DA, Fonkalsrud L, Hwang JH, Khashab MA, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Shaukat A, Shergill AK, Wang A, Cash BD, DeWitt JM. The management of antithrombotic agents for patients undergoing GI endoscopy. *Gastrointest Endosc* 2016; **83**: 3-16 [PMID: 26621548 DOI: 10.1016/j.gie.2015.09.035]

8 **Zuckerman MJ**, Hirota WK, Adler DG, Davila RE, Jacobson BC, Leighton JA, Qureshi WA, Rajan E, Hambrick RD, Fanelli RD, Baron TH, Faigel DO. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. *Gastrointest Endosc* 2005; **61**: 189-194 [PMID: 15729224 DOI: 10.1016/S0016-5107(04)02392-2]

9 **Lee SY**, Tang SJ, Rockey DC, Weinstein D, Lara L, Sreenarasimhaiah J, Choi KW. Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West. *Gastrointest Endosc* 2008; **67**: 1076-1081 [PMID: 18384789 DOI: 10.1016/j.gie.2007.11.037]

10 **DiSario JA**, Baskin WN, Brown RD, DeLegge MH, Fang JC, Ginsberg GG, McClave SA. Endoscopic approaches to enteral nutritional support. *Gastrointest Endosc* 2002; **55**: 901-908 [PMID: 12024148 DOI: 10.1067/mge.2002.124209]

11 **Eisen GM**, Baron TH, Dominitz JA, Faigel DO, Goldstein JL, Johanson JF, Mallery JS, Raddawi HM, Vargo JJ, Waring JP, Fanelli RD, Wheeler-Harbough J. Role of endoscopy in enteral feeding. *Gastrointest Endosc* 2002; **55**: 794-797 [PMID: 12024129]

12 **Luman W**, Kwek KR, Loi KL, Chiam MA, Cheung WK, Ng HS. Percutaneous endoscopic gastrostomy--indications and outcome of our experience at the Singapore General Hospital. *Singapore Med J* 2001; **42**: 460-465 [PMID: 11874149]

13 **Rosenberger LH**, Newhook T, Schirmer B, Sawyer RG. Late accidental dislodgement of a percutaneous endoscopic gastrostomy tube: an underestimated burden on patients and the health care system. *Surg Endosc* 2011; **25**: 3307-3311 [PMID: 21533968 DOI: 10.1007/s00464-011-1709-y]

14 **Singh D**, Laya AS, Vaidya OU, Ahmed SA, Bonham AJ, Clarkston WK. Risk of bleeding after percutaneous endoscopic gastrostomy (PEG). *Dig Dis Sci* 2012; **57**: 973-980 [PMID: 22138961 DOI: 10.1007/s10620-011-1965-7]

15 **McClave SA**, Chang WK. Complications of enteral access. *Gastrointest Endosc* 2003; **58**: 739-751 [PMID: 14595312 DOI: 10.1016/S0016-5107(03)02147-3]

16 **Tokunaga T**, Kubo T, Ryan S, Tomizawa M, Yoshida S, Takagi K, Furui K, Gotoh T. Long-term outcome after placement of a percutaneous endoscopic gastrostomy tube. *Geriatr Gerontol Int* 2008; **8**: 19-23 [PMID: 18713185 DOI: 10.1111/j.1447-0594.2008.00442]

17 **Jain R**, Maple JT, Anderson MA, Appalaneni V, Ben-Menachem T, Decker GA, Fanelli RD, Fisher L, Fukami N, Ikenberry SO, Jue T, Khan K, Krinsky ML, Malpas P, Sharaf RN, Dominitz JA. The role of endoscopy in enteral feeding. *Gastrointest Endosc* 2011; **74**: 7-12 [PMID: 21704804 DOI: 10.1016/j.gie.2010.10.021]

18 **Wollman B**, D'Agostino HB, Walus-Wigle JR, Easter DW, Beale A. Radiologic, endoscopic, and surgical gastrostomy: an institutional evaluation and meta-analysis of the literature. *Radiology* 1995; **197**: 699-704 [PMID: 7480742 DOI: 10.1148/radiology.197.3.7480742]

**P-Reviewer:** Kim ST, Kim CL **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 General demographics of patients included in the study**

|  |  |
| --- | --- |
| **All patients** | |
| **Patients (*n*)** | **320** |
| **Age (mean years ± SD)** | **65.03 ± 16.11** |
| **BMI (mean years ± SD)** | **28.47 ± 9.75** |
| **Gender**  **Male (n)**  **Female (n)** | **169**  **151** |

BMI: Body mass index.

**Table 2 Demographics and complications in patients taking clopidogrel *vs* patients not on clopidogrel**

|  |  |  |  |
| --- | --- | --- | --- |
| **Outcome** | **No plavix** | **Plavix** | ***P*-value** |
| **Patients (*n*)** | **286** | **33** | **-** |
| **Age (mean years ± SD)** | **64.37 ± 16.44** | **71.21 ± 11.43** | **0.02** |
| **BMI (mean years ± SD)** | **28.30 ± 9.59** | **29.25 ± 10.66** | **0.60** |
| **Hgb drop < 48 h** | **5** | **2** | **0.16** |
| **Local complications < 48 h** | **8** | **2** | **0.28** |
| **Transfusions < 48 h** | **7** | **2** | **0.24** |
| **Rescope < 48 h** | **1** | **1** | **0.20** |

BMI: Body mass index; Hgb: Hemoglobin.